Categories

“Bridging the Tribal Inequity Gap to Early Lung Cancer Screening” is an initiative aimed at increasing lung cancer screening rates in American Indian and Alaska Native (AI/AN) communities through a culturally tailored toolkit. Designed for both healthcare providers and community members, the toolkit raises awareness, shares best practices, and supports improved screening rates in historically underserved populations. This resource directly addresses systemic barriers—including access, trust, and cultural responsiveness—while equipping clinics and communities with practical, relevant educational resources. For your reference, here is a […]

AstraZeneca has presented the latest overall survival (OS) data (post-hoc analysis) for IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl) in the HIMALAYA study for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).1,2 IMFINZI + IMJUDO is the only FDA approved 1L IO regimen with 5-year OS data from the HIMALAYA Phase III study […]

Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial Longest survival follow-up ever reported for immunotherapy treatment in this setting  Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall […]

Takeda’s Compassionate Use Program for EXKIVITY is now open for enrollment in the U.S. The withdrawal of EXKIVITY will occur no later than March 2024, with the specific date still to be determined by the US Food and Drug Administration (FDA) based on review of ongoing operational activities related to the withdrawal. • Patients prescribed […]

KEYTRUDA® (pembrolizumab) Injection 100 mg is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC. SELECTED SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate. 1 month. Consider administration of other systemic immunosuppressants in […]

AstraZeneca recently shared the latest overall survival (OS) data for IMFINZI® (durvalumab) in combination with IMJUDO®(tremelimumab-actl) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).1,2  Primary AnalysisThe primary analysis demonstrated statistically significant improvement in the primary endpoint of OS vs sorafenib in the first-line (1L) treatment of uHCC1,2: *The HR is based on the stratified Cox proportional hazards […]

Takeda has announced that following discussions with the U.S. Food and Drug Administration (FDA), we will begin the process of voluntarily withdrawing EXKIVITY (mobocertinib) from the U.S. market over the next few months. EXKIVITY is currently indicated for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small […]

AstraZeneca recently announced that new data from the ADAURA trial regarding AGRISSO® (osimertinib) has been released. The ADAURA trial is an ongoing study of TAGRISSO as adjuvant therapy after tumor resection in adult patients with completely resected Stage IB-IIIA EGFRm (exon 19 deletions or exon 21 L858R mutations) non-small cell lung cancer (NSCLC). TAGRISSO was approved as […]

The Oklahoma Society of Clinical Oncology, Inc. would like to invite you to attend our 2022 Spring meeting. Join your colleagues to hear highlights from this state-of-the art symposium on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. The “Best of” SABCS is an officially licensed program of the San Antonio […]

Novartis is pleased to announce that SCEMBLIX® (asciminib) tablets is now approved for the treatment of adult patients with: ·  Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs) ○     This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval […]